Drug Profile
Pembrolizumab biosimilar - CinnaGen
Latest Information Update: 12 Oct 2022
Price :
$50
*
At a glance
- Originator CinnaGen
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 10 Oct 2022 No development reported - Phase-II for COVID-2019 infections in Iran (Combination therapy) (IV) (CinnaGen pipeline, October 2022)
- 06 Jun 2020 Phase-II clinical trials in COVID-2019 infections (Combination therapy) in Iran (IV) (IRCT20150303021315N19)